ArticleJAMA network open2026
Metformin Use and Development of Esophageal Squamous Cell Carcinoma.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Esophageal squamous cell carcinoma (ESCC) carries a poor prognosis, stressing the need for preventive measures. A decreased risk of ESCC among metformin users has been suggested, but evidence is limited. Objective: To assess whether metformin use, given its potential anticancer properties, is associated with risk of ESCC. Design, Setting, and Participants: This population-based case-control study set between 1994 and 2023 looked at data from all 5 Nordic countries (ie, Denmark, Finland, Iceland, Norway, and Sweden). Participants were patients newly diagnosed with ESCC during the study period, and each was compared with 10 times as many control participants randomly selected from the general population (matched by age, sex, calendar year, and country). Exposures: Use of metformin vs nonuse. Main Outcomes and Measures: Conditional logistic regression provided odds ratios (OR) with 95% CIs for the association between metformin use and the development of ESCC. In addition to the matching, the ORs were adjusted for tobacco smoking, alcohol overconsumption, use of nonsteroidal anti-inflammatory drugs or aspirin, and use of statins. A dose-response analysis was conducted among participants with at least 5 years of observation time, based on the defined daily dose during the 5-year period. Results: This study included 13 050 case patients with ESCC (8030 men [61.5%] and 5020 women [38.5%], diagnosed at a median age of 70 years [IQR, 62-77 years]), and 130 500 age- and sex-matched control participants. Metformin use was associated with a 36% lower odds of ESCC compared with nonuse (OR, 0.64; 95% CI, 0.59-0.69). The odds were especially lower in participants with a higher dosage of metformin (>1278 defined daily dose in 5 years: OR, 0.52; 95% CI, 0.44-0.61). Conclusions and Relevance: In this case-control study, metformin use was associated with substantially lower odds of ESCC. This finding should prompt investigations of metformin as a preventive option in high-risk individuals and as a potential future therapeutic agent for ESCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.